Genome&Company cuts convertible bond conversion price to KRW 5,240 from KRW 6,420

Genome&Company reset the conversion price on its unlisted 4th convertible bond to KRW 5,240 from KRW 6,420. Move increases shares issuable on conversion to 5,152,671 from 4,205,607 against KRW 27 billion outstanding principal. Reset takes effect Oct. 13, 2026, reflecting a market-price adjustment mechanism. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genome&Company published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261013900486), on October 13, 2026, and is solely responsible for the information contained therein. (C)